Sporadic amyotrophic lateral sclerosis with seropositive neuromyelitis optica spectrum disorder A case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jin Young | - |
dc.contributor.author | Oh, Hye Jeong | - |
dc.contributor.author | Kim, Yuntae | - |
dc.contributor.author | Seok, Jin Myoung | - |
dc.date.accessioned | 2021-09-10T05:49:19Z | - |
dc.date.available | 2021-09-10T05:49:19Z | - |
dc.date.issued | 2021-04-23 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18896 | - |
dc.description.abstract | Rationale: Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disorder of the central nervous system with an autoantibody against aquaporin-4 protein (AQP4), and amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. We report a female patient with ALS who had asymptomatic AQP4 antibody at the diagnosis of ALS, and NMOSD occurred 4 years later after the diagnosis of ALS. Patient concerns: She was already bedridden and had tracheostomy because of ALS which was diagnosed at her age of 55. At the time of her ALS diagnosis, she had no brain or spinal cord lesions, but was seropositive for AQP4 antibody. At her age of 59, new-onset complete paralysis of all extremities and severe pain on the posterior neck and both shoulders occurred and visited the hospital. Diagnosis: Longitudinally extensive transverse myelitis was diagnosed, which was the onset attack of seropositive NMOSD. The diagnosis was confirmed based on the international consensus diagnostic criteria for NMOSD with MR imaging, cerebrospinal fluid exam and laboratory work-ups with AQP4 antibody test. Interventions: High dose methylprednisolone was administered for 5 days. Plasma exchange as a further treatment was recommended, but she and her family refused. Outcomes: Her pain was relieved after steroid treatment, but there was no improvement of her leg weakness. Lessons: This case is a rare combination of neuroinflammatory and neurodegenerative diseases. Considering the alterations of blood-brain barrier along with the progression of ALS, it highlights that the consequence of ALS pathogenesis might affect the development of NMOSD. And the careful follow-up is recommended even in patients with profound weakness, especially if those who were at risk of developing certain neurological disorders. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Sporadic amyotrophic lateral sclerosis with seropositive neuromyelitis optica spectrum disorder A case report | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MD.0000000000025580 | - |
dc.identifier.scopusid | 2-s2.0-85105761152 | - |
dc.identifier.wosid | 000659089900062 | - |
dc.identifier.bibliographicCitation | Medicine, v.100, no.16, pp 1 - 4 | - |
dc.citation.title | Medicine | - |
dc.citation.volume | 100 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 4 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CORD BARRIER | - |
dc.subject.keywordAuthor | amyotrophic lateral sclerosis | - |
dc.subject.keywordAuthor | anti-aquaporin-4 antibody | - |
dc.subject.keywordAuthor | neuromyelitis optica spectrum disorder | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.